ライフサイエンスコーパス: beclomethasone

1 eline in daytime symptom score was -0.62 for beclomethasone, -0.41 for montelukast, and -0.17 for pla

2 used the clinically relevant corticosteroid beclomethasone-17-monopropionate (17-BMP) to assess GR f

3 lukast, 10 mg once daily at bedtime; inhaled beclomethasone, 200 microg twice daily, administered wit

4 ily beclomethasone treatment was one puff of beclomethasone (40 mug per puff) or placebo given in the

5 change from baseline in FEV1 was 13.1% with beclomethasone, 7.4% with montelukast, and 0.7% with pla

6 d costs of extrafine hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pr

7 almeterol was inferior to the combination of beclomethasone and salmeterol as judged by protection ag

8 d salmeterol to that with the combination of beclomethasone and salmeterol in moderate asthma.

9 1; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and 0.9% other or unspecified glucocorti

10 One hundred twenty-three infants received beclomethasone, and 130 received placebo.

11 nisolide-CFC - 936; triamcinolone-CFC - 787; beclomethasone-CFC - 548; fluticasone DPI - 445; budeson

12 For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry

13 ith placebo for each end point; P < 0.01 for beclomethasone compared with montelukast for each end po

14 reatment compared with placebo; P < 0.01 for beclomethasone compared with montelukast).

15 reatment compared with placebo; P < 0.01 for beclomethasone compared with montelukast).

16 placebo (in a 2:1 ratio) in combination with beclomethasone dipropionate (6 to 16 inhalations per day

17 e exposed to 0.1 mug/L, 1 mug/L, or 10 mug/L beclomethasone dipropionate (BCMD) via a flow-through sy

18 ts of two widely prescribed glucocorticoids, beclomethasone dipropionate (BDP) and prednisolone aceta

19 ability of dexamethasone (DEX) in vitro and beclomethasone dipropionate (BDP) in vivo to induce beta

20 fish model and the synthetic glucocorticoid beclomethasone dipropionate (BDP) to investigate the rol

21 We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastroin

22 ment period and a 6-wk treatment period with beclomethasone dipropionate (BDP), 336 microg/d.

23 Beclomethasone dipropionate (BDP), a topically active st

24 cle aerosols such as HFA-ciclesonide and HFA-beclomethasone dipropionate (HFA-BDP) enables a higher d

25 hows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily.

26 V1 ; FEV1 <65% vs >/=65% predicted], inhaled beclomethasone dipropionate dose [<600 vs >/=600 mug/day

27 nts were 100 and 800 micron/d of an HFA-134a beclomethasone dipropionate formulation.

28 on 60 minutes after inhalation of 800 microg beclomethasone dipropionate in six healthy subjects.

29 re bundles with the synthetic glucocorticoid beclomethasone dipropionate increased the phosphorylatio

30 seventy-four patients with asthma receiving beclomethasone dipropionate or triamcinolone acetonide d

31 twice per day, equivalent to 800 mug per day beclomethasone dipropionate) or placebo.

32 effectiveness of an inhaled corticosteroid (beclomethasone dipropionate) used as rescue treatment.

33 Beclomethasone dipropionate, 84 microg twice a day, was

34 Participants received 6 weeks of inhaled beclomethasone dipropionate.

35 ents before and after treatment with inhaled beclomethasone, DNO averaged 6.8 +/- 1.2, 25.5 +/- 3.8,

36 Prescribed HFA-beclomethasone doses were lower (P < .001) than fluticas

37 oup at 28 days of age, and 18 percent in the beclomethasone group and 20 percent in the placebo group

38 similar in the two groups: 43 percent in the beclomethasone group and 45 percent in the placebo group

39 had severe adverse events; one in the daily beclomethasone group had viral meningitis and one in the

40 At 28 days of age, fewer infants in the beclomethasone group than in the placebo group were rece

41 lomethasone plus albuterol as rescue (rescue beclomethasone group); and twice daily placebo with plac

42 with placebo plus albuterol as rescue (daily beclomethasone group); twice daily placebo with beclomet

43 Although beclomethasone had a greater mean clinical benefit than

44 Although beclomethasone had a larger mean effect than montelukast

45 Patients started on HFA-beclomethasone had significantly higher odds (adjusted o

46 (n=71), daily beclomethasone (n=72), rescue beclomethasone (n=71), and placebo (n=74)-555 individual

47 our treatment groups; combined (n=71), daily beclomethasone (n=72), rescue beclomethasone (n=71), and

48 to 80 years receiving their first ICS as HFA-beclomethasone or fluticasone and matched on baseline de

49 ue beclomethasone treatment was two puffs of beclomethasone or placebo for each two puffs of albutero

50 d a randomized, multicenter trial of inhaled beclomethasone or placebo in 253 infants, 3 to 14 days o

51 approaches including topical agents such as beclomethasone or sirolimus as a steroid-free approach t

52 ment groups: twice daily beclomethasone with beclomethasone plus albuterol as rescue (combined group)

53 lomethasone group); twice daily placebo with beclomethasone plus albuterol as rescue (rescue beclomet

54 ent outcomes were similar or better with HFA-beclomethasone prescribed at significantly lower doses a

55 5% CI, $165-$620) per patient prescribed HFA-beclomethasone rather than fluticasone.

56 care costs were significantly lower for HFA-beclomethasone than fluticasone (mean, $1869 [95% CI, $1

57 Early beclomethasone therapy did not prevent bronchopulmonary

58 Twice daily beclomethasone treatment was one puff of beclomethasone

59 Rescue beclomethasone treatment was two puffs of beclomethasone

60 Beclomethasone was delivered in a decreasing dosage, fro

61 to one of four treatment groups: twice daily beclomethasone with beclomethasone plus albuterol as res

62 erol as rescue (combined group); twice daily beclomethasone with placebo plus albuterol as rescue (da